Bing

SEARCH HISTORY

In addition to specific proprietary factors, Trade-Ideas identified Celgene as such a stock due to the following factors: CELG has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $804.1 million. CELG has ...
The Street · 7/21/2015
Celgene
Bass' first review, on Feb. 10 against an Acorda Therapeutics patent on the Ampyra multiple sclerosis drug, led to a nearly 10 percent drop in the company's stock price. Celgene's patents cover methods to ensure that thalidomide and related cancer drugs ...
CNBC · 7/29/2015
Tenet Healthcare Corp (THC): THC stock is down 0.6% today. Celgene Corp (CELG): CELG stock is down 0.5%, marking the fourth consecutive day the stock has decreased. Natus Medical Inc (BABY): BABY stock is down 0.4% today. Tornier N.V. (TRNX) …
Investor Place · 10 hours ago
We have highlighted some of the key stats from this just-revealed announcement below: Earnings: Celgene earnings were in line with expectations. Our consensus called for EPS of $1.08 and the company reported EPS of $1.08 (including stock-based …
ZACKS · 7/23/2015
Celgene
There is potential upside of 6.2% for shares of Celgene based on a current price of $131.59 and an average consensus analyst price target of $139.73. The stock should discover initial support at its 50-day moving average (MA) of $118.87 and subsequent ...
Financial News Network Online · ByPeter Chu · 7/27/2015
Seattle biotech Juno Therapeutics (Nasdaq: JUNO) is only about two years old, but it has already made biotech history in many ways. All of this success goes against a broader narrative of the difficulties of being a young biotech company in the Puget …
The Business Journal · 7/22/2015
But Cowen analyst Eric Schmidt, see more upside ahead for the stock, raising his price target from $146 to $150. As he writes: We expect CELG shares to outperform based on greater investor appreciation of the company’s improved pipeline and …
Barron's · ByJohanna Bennett · 7/23/2015
Celgene alleged that the real motive of Kyle Bass and his partners was to make money short-selling the shares of pharmaceutical companies. The stock prices of pharmaceutical companies declined when the Coalition …
Value Walk · ByMarie Cabural · 1 day ago
The limited resources of the agency can't be wasted on stock trading schemes." The motion, filed by Dominic Cerrito of Quinn Emanuel Urquhart & Sullivan and Anthony Insogna of Jones Day, makes interesting reading.
Managing Intellectual Property · 7/29/2015
Celgene
Celgene Corporation (NASDAQ:CELG) today announced that its direct wholly-owned subsidiary, Strix Corporation, has commenced its previously announced tender offer for all outstanding shares of common stock of Receptos, Inc. (NASDAQ: RCPT) at a …
4 Traders · 7/28/2015

Celgene

Company
Celgene Corporation is an American biotechnology company that manufactures drug therapies for cancer and inflammatory disorders. I…
Celgene Corporation is an American biotechnology company that manufactures drug therapies for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major products are Thalomid, which is approved for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum, as well as in combination with dexamethasone for patients with newly diagnosed multiple myeloma, and Revlimid, for which the company has received FDA and EMA approval in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate …
Data from: Wikipedia